Combination of sorafenib, vorinostat and bortezomib for the treatment of poor-risk AML: report of two consecutive clinical trials

Hamid Sayar, Larry D. Cripe, Antoine N. Saliba, Mohammad Abu Zaid, Heiko Konig, H. Scott Boswell

Research output: Contribution to journalLetter

3 Scopus citations
Original languageEnglish (US)
Pages (from-to)30-33
Number of pages4
JournalLeukemia Research
StatePublished - Feb 2019


  • AML
  • Acute myeloid leukemia
  • Bortezomib
  • Sorafenib
  • Vorinostat

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this